EP263/#849 Olaparib treatment in patients with platinum-sensitive relapsed ovarian cancer by BRCA mutation and homologous recombination deficiency status: characterization of long-term/short-term treatment duration in light

Ying Liu,Jiefen Munley,Cara Mathews,Diane Provencher,Carol Aghajanian,Lucy Gilbert,Adam Einaggar,Karen Cadoo,Alon Altman,Destin Black,Colleen Mccormick,Nashwa Kabil,Fiona Simpkins,Alan Barnicle,Rosie Taylor

doi:10.1136/ijgc-2022-igcs.354

EP263/#849 Olaparib treatment in patients with platinum-sensitive relapsed ovarian cancer by BRCA mutation and homologous recombination deficiency status: characterization of long-term/short-term treatment duration in light

Ying Liu, Jiefen Munley + Show 13 more

Open Access

https://doi.org/10.1136/ijgc-2022-igcs.354

Copy DOI

Journal: International Journal of Gynecologic Cancer

Publication Date: Dec 1, 2022

Affiliation: Memorial Sloan Kettering Cancer Center, National Patient Safety Foundation, AstraZeneca (United States), Women & Infants Hospital of Rhode Island, Brown University, Centre Hospitalier de l’Université de Montréal, McGill University Health Centre, West Cancer Center, CancerCare Manitoba, University of Manitoba, Willis-Knighton Cancer Center, University of Pennsylvania, AstraZeneca (United Kingdom)

#Homologous Recombination Deficiency Status #Platinum-sensitive Relapsed Ovarian Cancer + Show 8 more

Abstract
Full-Text PDF
Similar Papers

Abstract

ObjectivesThe LIGHT study (NCT02983799) demonstrated the activity of olaparib treatment in patients with platinum-sensitive relapsed ovarian cancer (PSROC) and known BRCA mutation (BRCAm) and homologous recombination deficiency (HRD) status (Mathews...

Full Text

Paper version not known

Open DOI Link

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Paper Title

Journal

Date

Author

View more papers

More From: International Journal of Gynecologic Cancer

Paper Title

Journal

Date

Author

View more papers

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.